Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Overall Survival (OS) Compared to Chemotherapy in Patients with Advanced Esophageal or Esophagogastric Junction Carcinoma Whose Tumors Express PD-L1 (CPS ≥10)

Wed November 14, 2018 6:45 AM|Business Wire|About: MRK 

  Lilly Announces Positive Results for Emgality® (galcanezumab-gnlm) from the CONQUER Study in Patients who Failed Previous Migraine Preventive Treatments

08/05/2019 

 Failure to respond to migraine preventive treatments is a common occurrence; internationally it is estimated that more than 40% of patients who use migraine preventive medications have a history of failure or switching treatments(1)

INDIANAPOLIS, Aug. 5, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) 

CMS Grants New Technology Add-On Payment for Inpatient Use of AZEDRA® (iobenguane I 131)

Tue August 6, 2019 8:30 AM|GlobeNewswire|About: PGNXGlobeNewswire

NEW YORK, Aug. 06, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (PGNX),

 https://www.progenics.com/product-pipeline/overview/ 

 https://ir.progenics.com/news-releases/news-release-details/cms-grants-new-technology-add-payment-inpatient-use-azedrar 

 Merck Begins Rolling Submission of Licensure Application for V920 (rVSV∆G-ZEBOV-GP) to U.S. Food and Drug Administration

Tue November 13, 2018 4:35 PM|Business Wire|About: MRK 

 Lyfebulb Partners with Celgene to Inspire Patient-Driven Innovation in the Management of Multiple Sclerosis

Wed November 14, 2018 7:58 AM|PR Newswire|About: CELG

NEW YORK, Nov. 14, 2018 /PRNewswire/

 November 14, 2018 

AbbVie Presents Positive Phase 3 Data Demonstrating Investigational Elagolix Reduces Heavy Menstrual Bleeding in Women with Uterine Fibroids at 2018 AAGL Global Congress

 NORTH CHICAGO, Ill., Nov. 14, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV) 

  Nektar Therapeutics and Bristol-Myers Squibb Announce U.S. FDA Breakthrough Therapy Designation for Bempegaldesleukin (NKTR-214) in Combination with Opdivo® (nivolumab) for the Treatment of Patients with Untreated Advanced Melanoma

Thu August 1, 2019 7:00 AM|PR Newswire|About: BMY, NKTR 

 SAN FRANCISCO, Aug. 1, 2019 /PRNewswire/ -- Nektar Therapeutics (NKTR) and Bristol-Myers Squibb (BMY) 

 Two Phase 3 Studies of the Triple Combination of VX-659, Tezacaftor and Ivacaftor Met Primary Endpoint of Improvement in Lung Function (ppFEV1) in People with Cystic Fibrosis

Tue November 27, 2018 8:00 AM|Business Wire|About: VRTX 

 AstraZeneca Presents Clinical Research Advances for Blood Cancer Patients at 2018 American Society of Hematology Annual Meeting

Tue November 27, 2018 7:00 AM|Business Wire|About: AZN 

Wed August 14, 2019 8:00 AM|Business Wire|About: AZN

Designation based on positive results from two Phase III trials

WILMINGTON, Del.--(BUSINESS WIRE)

 https://seekingalpha.com/pr/17603088-calquence-acalabrutinib-granted-us-breakthrough-therapy-designation-chronic-lymphocytic 

 Pfizer Receives Six Months Pediatric Exclusivity for LYRICA® (pregabalin)

Tue November 27, 2018 3:01 PM|Business Wire|About: PFE 

 Bayer's hemophilia A treatment Jivi OK'd in Europe

Nov. 27, 2018 11:15 AM ET|About: Bayer A.G. ADR (BAYRY)|By: Douglas W. House, SA News Editor 

Teva’s Generic Version of EpiPen® (Epinephrine Injection, USP) Auto-Injector 0.3 mg Now Available in Limited Quantity in the United States

Tue November 27, 2018 10:06 AM|Business Wire|About: TEVA

PARSIPPANY, N.J.--(BUSINESS WIRE)-- Teva Pharmaceutical Industries (TEVA) 

 Medtronic's Valiant Navion stent CE Mark'd

Nov. 13, 2018 10:23 AM ET|About: Medtronic plc (MDT)|By: Douglas W. House, SA News Editor  

 Sobi to acquire U.S. rights to AstraZeneca's Synagis and half interest in MEDI8897 for $1.5B

Nov. 13, 2018 8:34 AM ET|About: AstraZeneca Group plc (AZN)|By: Douglas W. House, SA News Editor  

 Ebola clinical trial to begin in DRC

Nov. 13, 2018 4:49 AM ET|By: Yoel Minkoff, SA News Editor  

 
Helen Branswell 

 Enanta’s HCV Collaboration Partner AbbVie receives Approval by the European Commission for MAVIRET™ (glecaprevir/pibrentasvir) to Shorten Treatment Duration to Eight Weeks for Treatment-Naïve HCV Patients with Compensated Cirrhosis

Fri August 2, 2019 8:51 AM|Business Wire|About: ENTA 

 WATERTOWN, Mass.--(BUSINESS WIRE)-- Enanta Pharmaceuticals, Inc. (ENTA) 

 Novocure Announces More than 70 Presentations on Tumor Treating Fields at 23rd Annual Meeting of the Society for Neuro-Oncology

Tue November 13, 2018 8:24 AM|Business Wire|About: NVCR

 ST. HELIER, Jersey--(BUSINESS 

WIRE)-- Novocure (NVCR)  

 Real-World Evidence on Patients Aged 80 and Older Presented From ARISTOPHANES, the Largest Real-World Data Study Evaluating Oral Anticoagulants Among Patients with Non-Valvular Atrial Fibrillation

Eliquis® (apixaban) was associated with lower rates of stroke or systemic embolism and major bleeding in elderly patient populations when compared to rivaroxaban and dabigatran

 (PRINCETON, N.J. & NEW YORK) November 11, 2018 – The Bristol-Myers Squibb-Pfizer Alliance  

 New Data from Investigational Study of LENVIMA® (lenvatinib) and KEYTRUDA® (pembrolizumab) Combination in Three Different Tumor Types Presented at the Society for Immunotherapy of Cancer’s 33rd Annual Meeting

Fri November 9, 2018 6:45 AM|Business Wire|About: MRK 

 TOKYO & KENILWORTH, N.J.--(BUSINESS WIRE)-- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Merck (MRK), known as MSD outside the United States and Canada,  

 FARXIGA Significantly Reduced Hospitalization for Heart Failure or CV Death in a Broad Patient Population with Type 2 Diabetes in the Landmark DECLARE-TIMI 58 Trial

Sat November 10, 2018 4:45 PM|Business Wire|About: AZN 

Lynparza Phase III PROfound trial in HRR* mutation-selected metastatic castration-resistant prostate cancer met primary endpoint

PUBLISHED7 August 2019 

 7 August 2019 07:00 BST

AstraZeneca and MSD’s Lynparza met the primary endpoint of significantly increasing the time patients selected for BRCA1/2 or ATM mutations live without radiographic disease progression vs. standard of care treatment

Only PARP inhibitor with positive Phase III results in four different cancer types (ovarian, breast, pancreatic and prostate)

AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc

 AstraZeneca and Merck's Lynparza shows treatment benefit in late-stage prostate cancer study

Aug. 7, 2019 7:04 AM ET|About: AstraZeneca PLC (AZN)|By: Douglas W. House, SA News Editor 

 https://seekingalpha.com/news/3488293-astrazeneca-mercks-lynparza-shows-treatment-benefit-late-stage-prostate-cancer-study 

 Lynparza Phase III PAOLA-1 trial met primary endpoint as 1st-line maintenance treatment with bevacizumab for advanced ovarian cancer 

AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada)

 https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2019/lynparza-phase-iii-paola-1-trial-met-primary-endpoint-as-1st-line-maintenance-treatment-with-bevacizumab-for-advanced-ovarian-cancer-14082019.html 

 Amgen Presents Results Highlighting The Long-Term Safety And Efficacy Of Repatha® (Evolocumab) In The Longest Duration Study Of A PCSK9 Inhibitor To Date At AHA Scientific Sessions 2018

Mon November 12, 2018 4:00 PM|PR Newswire|About: AMGN 

 THOUSAND OAKS, Calif., Nov. 12, 2018 /PRNewswire/ -- Amgen (AMGN)  

 Mirati's mocetinostat + AstraZeneca's Imfinzi show positive effect in mid-stage lung cancer study

Nov. 9, 2018 9:30 AM ET|About: AstraZeneca Group plc (AZN)|By: Douglas W. House, SA News Editor  

 ODYSSEY OUTCOMES Investigators Highlight at AHA that Praluent® (alirocumab) Injection Was Associated with Fewer Deaths from Any Cause

Sun November 11, 2018 8:14 AM|PR Newswire|About: REGN

TARRYTOWN, N.Y. and PARIS, Nov. 11, 2018 /PRNewswire/ --

 Amgen Announces Presentation Of Research Reinforcing The Long-Term Safety And Efficacy Of Repatha® (Evolocumab) In High-Risk Patients At AHA Scientific Sessions 2018

Mon November 5, 2018 4:00 PM|PR Newswire|About: AMGN 

Mon September 9, 2019 3:20 AM|PR Newswire|About: LLY 

 PR Newswire

INDIANAPOLIS, Sept. 9, 2019 /PRNewswire/ -- Eli Lilly and Company (LLY) 

 https://www.prnewswire.com/news-releases/lilly-announces-positive-results-for-selpercatinib-loxo-292-demonstrating-a-68-percent-objective-response-rate-and-sustained-durability-in-heavily-pretreated-ret-fusion-positive-non-small-cell-lung-cancer-300913590.html 

 Dupixent® (dupilumab) Showed Positive Topline Results in Phase 3 Trial of Children Aged 6 to 11 Years with Severe Atopic Dermatitis

Tue August 6, 2019 1:04 AM|PR Newswire|About: REGN

TARRYTOWN, N.Y. and PARIS, Aug. 6, 2019 /PRNewswire/ --

U.S. FDA submission for children planned for 4Q 2019

Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi 

 https://www.prnewswire.com/news-releases/dupixent-dupilumab-approved-by-european-commission-for-adolescents-with-moderate-to-severe-atopic-dermatitis-300896737.html 

Mon September 16, 2019 6:00 AM|GlobeNewswire|About: AMRN

Millions of Patients on Statins with Elevated Triglycerides Are at Risk of Cardiovascular Events, Such as Heart Attack, Stroke or Death

Icosapent Ethyl Recognized as Only Non-LDL-Cholesterol Lipid Management Treatment with Cardiovascular Risk Reduction Outcomes Results

DUBLIN, Ireland and BRIDGEWATER, N.J., Sept. 16, 2019 (GLOBE NEWSWIRE) -- Amarin Corporation plc (AMRN)

 Lilly and NextCure Announce Collaboration to Discover and Develop Novel Immuno-Oncology Medicines

Mon November 5, 2018 4:30 PM|PR Newswire|About: LLY 

  August 12, 2019 at 10:01 AM EDT

TARRYTOWN, N.Y., Aug. 12, 2019 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)

 Illumina to Acquire Pacific Biosciences for Approximately $1.2 Billion, Broadening Access to Long-Read Sequencing and Accelerating Scientific Discovery

Thu November 1, 2018 4:02 PM|Business Wire|About: ILMN, PACB 

Fri August 9, 2019 4:05 PM|PR Newswire|About: AMGN

PR Newswire

THOUSAND OAKS, Calif., Aug. 9, 2019 /PRNewswire/ -- Amgen (AMGN)

 https://www.enbrel.com/ 

 Genentech’s Tecentriq® (ATEZOLIZUMAB) Plus Platinum-based Chemotherapy Reduced the Risk of Disease Worsening or Death in People With Previously Untreated Advanced Bladder Cancer

Mon August 5, 2019 1:00 AM|Business Wire|About: RHHBY

– IMvigor130 is the first positive Phase III study of a cancer immunotherapy combination in previously untreated advanced bladder cancer –

– Data will be shared with health authorities globally, including the U.S. Food and Drug Administration (FDA) –

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY)

 https://www.businesswire.com/news/home/20190804005062/en/ 

 Bavarian Nordic launches Phase 1/2 study of prime/boost vaccine CV301 in colorectal and pancreatic cancers

Nov. 2, 2018 11:47 AM ET|By: Douglas W. House, SA News Editor  

 AbbVie Submits New Drug Application to US FDA for Investigational Elagolix for Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Women

Mon August 5, 2019 8:30 AM|PR Newswire|About: ABBV, NBIX 

 PR Newswire

NORTH CHICAGO, Ill., Aug. 5, 2019 /PRNewswire/ -- AbbVie (ABBV)

.

 https://www.prnewswire.com/news-releases/abbvie-submits-new-drug-application-to-us-fda-for-investigational-elagolix-for-management-of-heavy-menstrual-bleeding-associated-with-uterine-fibroids-in-women-300896046.html 

 BioArctic's Partner AbbVie Exercises its Option to License the Alpha-synuclein Antibody Portfolio for Parkinson's  Disease

 Thu November 1, 2018 11:09 PM|PR Newswire|About: ABBV, B, BIOA

STOCKHOLM, Oct. 2, 2018 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B)

 FDA OKs expanded use for Novartis' Promacta

Nov. 16, 2018 4:43 PM ET|About: Novartis AG (NVS)|By: Douglas W. House, SA News Editor 

 European advisory group backs ViiV Healthcare's Tivicay + lamivudine in HIV-1

Nov. 19, 2018 7:14 AM ET|By: Douglas W. House, SA News Editor  

 August 08, 2019

Gilead Sciences Statement on U.S. Food and Drug Administration Advisory Committee’s Recommendation on Descovy for PrEP™

FOSTER CITY, Calif.--(BUSINESS WIRE)--Aug. 7, 2019-- Gilead Sciences, Inc. (NASDAQ: GILD

 https://seekingalpha.com/pr/17597519-gilead-sciences-statement-u-s-food-drug-administration-advisory-committee-s-recommendation 

Fri August 9, 2019 7:00 AM|Business Wire|About: AZN

TAGRISSO is the only medicine demonstrating statistically-significant overall survival benefit in this setting. Also increased the time patients with central nervous system metastases lived without disease progression

WILMINGTON, Del.--(BUSINESS WIRE)-- AstraZeneca

 BriaCell to Present Updated Clinical Data Including Early Safety Data in KEYTRUDA® Combination Study and Positive Phase IIa Monotherapy Efficacy Data at 2018 San Antonio Breast Cancer Symposium

Mon November 19, 2018 6:30 AM|GlobeNewswire|About: BCTXF, MRK 

Glaxo files U.S. marketing application for expanded use of Nucala

Nov. 19, 2018 7:46 AM ET|By: Douglas W. House, SA News Editor 

 U.S. FDA Approves DAURISMO™ (glasdegib) for Adult Patients with Newly-Diagnosed Acute Myeloid Leukemia (AML) for Whom Intensive Chemotherapy is Not an Option

Wed November 21, 2018 1:40 PM|Business Wire|About: PFE 

 AbbVie Receives US FDA Accelerated Approval for VENCLEXTA® (venetoclax) for Treatment of Newly-Diagnosed Acute Myeloid Leukemia Patients Ineligible for Intensive Chemotherapy

Wed November 21, 2018 2:14 PM|PR Newswire|About: ABBV 

 Janssen Announces U.S. FDA Accelerated Approval for SIRTURO® (bedaquiline) as Part of Combination Therapy to Treat Adolescents with Pulmonary Multidrug-Resistant Tuberculosis

Label expansion marks important milestone in Johnson & Johnson’s pediatric research and development program for bedaquiline

TITUSVILLE, NJ, August 9, 2019 — The Janssen Pharmaceutical Companies of Johnson & Johnson

 Analysts Take Action on Health Care Stocks

JPMorgan initiates coverage of BeiGene, Brookline Capital Markets starts covering Celsion and Cellectar Biosciences 

November 21, 2018 

 Alberto Abaterusso 

 BGNE CLSN CLRB 

 UPDATE - BriaCell to Present Updated Clinical Data Including Early Safety Data in KEYTRUDA® Combination Study and Positive Phase IIa Monotherapy Efficacy Data at 2018 San Antonio Breast Cancer Symposium

November 20, 2018 | About: BCTXF +0% MRK +0%

Note: This Press Release contains amendments to the press release previously issued on Nov. 19, 2018

 Myriad Will Seek FDA Approval of BRACAnalysis CDx® As a Companion Diagnostic for Lynparza® (olaparib) In Men with Metastatic Castrate-Resistant Prostate Cancer

Wed August 7, 2019 7:05 AM|GlobeNewswire|About: AZN, MYGN

SALT LAKE CITY, Aug. 07, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics (MYGN), Inc. (NASDAQ: MYGN)

Tue August 13, 2019 7:00 AM|PR Newswire|About: REGNQ2: 08-06-19 Earnings Summary

• Transcript

EPS of $6.02 beats by $0.60 Revenue of $1.93B (20.25% Y/Y) beats by $131.71M

TARRYTOWN, N.Y., Aug. 13, 2019 /PRNewswire/ -

 https://www.prnewswire.com/news-releases/fda-approves-eylea-aflibercept-injection-prefilled-syringe-300900436.html 

 Priority Review Granted to BeiGene’s New Drug Applications for Zanubrutinib and Tislelizumab in China

Thu November 15, 2018 7:00 AM|GlobeNewswire|About: BGNE 

 Exelixis’ Partner Ipsen Receives European Commission Approval for CABOMETYX® (cabozantinib) Tablets for the Treatment of Hepatocellular Carcinoma in Adults Previously Treated with Sorafenib

Thu November 15, 2018 1:32 AM|Business Wire|About: EXEL 

 FDA Grants Breakthrough Therapy Designation to ADCETRIS® (Brentuximab Vedotin) for Frontline Peripheral T-Cell Lymphomas

Thu November 15, 2018 8:00 AM|Business Wire|About: SGEN 

 New Approvals Allow Chronic Pain Sufferers to Try Abbott's Non-Opioid Pain Therapy Before Getting Device Implant

Thu November 15, 2018 9:00 AM|PR Newswire|About: ABT 

 CVS Health Teams Up with Philadelphia Job Corps, Philadelphia Works and Philadelphia Youth Network to Open New Mock Pharmacy for Aspiring Pharmacy Technicians

Thu November 15, 2018 8:00 AM|PR Newswire|About: CVS 

 PHILADELPHIA, Nov. 15, 2018 /PRNewswire/  

 Novo Nordisk's PIONEER 9 trial successfully meets primary endpoints

Nov. 23, 2018 7:40 AM ET|About: Novo Nordisk A/S (NVO)|By: Mamta Mayani, SA News Editor 

 European Commission Approves Spark Therapeutics’ LUXTURNA® (voretigene neparvovec), a One-time Gene Therapy for Inherited Retinal Disease Caused by Confirmed Biallelic RPE65 Mutations

Fri November 23, 2018 1:15 AM|GlobeNewswire 

Spark Therapeutics (ONCE) will manufacture and supply LUXTURNA for Novartis, while Novartis has exclusive rights to pursue development, registration and commercialization in all other countries outside the U.S.

PHILADELPHIA, Nov. 23, 2018 (GLOBE NEWSWIRE) -- Spark Therapeutics

Decision represents the fifth European approval in five years

August 13, 2019 07:08 AM Eastern Daylight Time

BEERSE, Belgium--(BUSINESS WIRE)--The Janssen Pharmaceutical Companies of Johnson & Johnson

AstraZeneca's Fasenra an Orphan Drug in U.S. for rare type of blood vessel inflammation

Nov. 26, 2018 6:46 AM ET|About: AstraZeneca Group plc (AZN)|By: Douglas W. House, SA News Editor  

Tue August 27, 2019 4:16 PM|Business Wire|About: BMY 

 ViiV Healthcare's HIV med Juluca OK'd in Japan

Nov. 26, 2018 7:33 AM ET|By: Douglas W. House, SA News Editor 

 Lilly to Present Clinical Data for Verzenio® (abemaciclib) and Real-World Evidence across HR+, HER2- Metastatic Breast Cancer at 2018 SABCS

Thu November 29, 2018 6:45 AM|PR Newswire|About: LLY 

European Commission Approves Merck’s DELSTRIGO™ (doravirine / lamivudine / tenofovir disoproxil fumarate), a Once-Daily Fixed-Dose Combination Tablet as a Complete Regimen and PIFELTRO™ (doravirine), an NNRTI, Both for the Treatment of HIV-1 in Appropriate Patients

 Wednesday, November 28, 2018 4:30 pm EST  KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK) 

 Eyenovia's micro-dose latanoprost shows positive effect in mid-stage study

Nov. 28, 2018 4:33 PM ET|By: Douglas W. House, SA News Editor  

 Amgen opts in on second cancer program with Nuevolution

Nov. 29, 2018 6:55 AM ET|About: Amgen Inc. (AMGN)|By: Douglas W. House, SA News Editor  

 Alkermes Announces Positive Topline Results From ENLIGHTEN-2 Phase 3 Study of ALKS 3831 in Patients With Schizophrenia

Thu November 29, 2018 7:01 AM|PR Newswire|About: ALKS 

 Varian Halcyon Treatment System Receives China NMPA Approval

Wed November 28, 2018 4:10 PM|PR Newswire|About: VAR 

 FDA Approves the ACTPen for Genentech’s Actemra, a Single-Dose, Prefilled Autoinjector for the Treatment of Rheumatoid Arthritis, Giant Cell Arteritis and Two Forms of Juvenile Arthritis

Mon November 26, 2018 11:35 AM|Business Wire|About: CHGCY, RHHBY 

 GW Pharma's Epidiolex successful in second late-stage study in Dravet syndrome

Nov. 26, 2018 7:16 AM ET|About: GW Pharmaceuticals plc (GWPH)|By: Douglas W. House, SA News Editor 

 Opthea completes enrollment in mid-stage study of OPT-302 in wet AMD

Nov. 26, 2018 11:48 AM ET|About: Opthea Limited ADR (CKDXY)|By: Douglas W. House, SA News Editor  

 Zymeworks and BeiGene Announce License and Collaboration Agreement for Zymeworks’ HER2-Targeted Therapeutic Candidates, ZW25 and ZW49, in Asia-Pacific and Research and License Agreement for Zymeworks’ Azymetric™ and EFECT™ Platforms Globally

Tue November 27, 2018 6:30 AM|Business Wire|About: BGNE, ZYME 

 FDA Approves Vitrakvi® (larotrectinib), the First Ever TRK Inhibitor, for Patients with Advanced Solid Tumors Harboring an NTRK Gene Fusion(1,2)

Mon November 26, 2018 7:16 PM|GlobeNewswire|About: LOXO 

 Celgene Corporation and bluebird bio Complete Enrollment of Pivotal KarMMa Study of anti-BCMA Car T Cell Therapy bb2121 in Patients with Relapsed and Refractory Multiple Myeloma

Tue November 27, 2018 7:30 AM|Business Wire|About: BLUE, CELG

SUMMIT, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Celgene Corporation (CELG) and bluebird bio, Inc. (BLUE)

 November 6, 2018

AbbVie Announces HUMIRA® (adalimumab) Global Patent License with Momenta

 NORTH CHICAGO, Ill., Nov. 6, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV) 

 FDA OKs Bristol-Myers Squibb's Empliciti for treatment-resistant myeloma

Nov. 6, 2018 4:51 PM ET|About: Bristol-Myers Squibb C... (BMY)|By: Douglas W. House, SA News Editor 

 Two Studies Measure Performance of ACUVUE OASYS with Transitions Light Intelligent Technology Contact Lenses in Simulated Sunlight, Day and Night Driving Conditions

Tue November 6, 2018 9:19 AM|PR Newswire|About: JNJ 

 Alkermes Presents New Data on ALKS 4230 at Society for Immunotherapy of Cancer's (SITC) 33rd Annual Meeting

Tue November 6, 2018 8:01 AM|PR Newswire|About: ALKS 

 Sorrento Therapeutics Anti-CEA CAR-T Demonstrates Significant Therapeutic Activity With Increased Overall Survival in Pancreatic Cancer Patients With Liver Metastases

Tue November 6, 2018 8:01 AM|GlobeNewswire|About: SRNE 

 SAN DIEGO, Nov. 06, 2018 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (SRNE) ("Sorrento") 

 TUV Rheinland OpenSky helps insulin pump by Insulet achieve cybersecurity certification by DTSec

Tue November 6, 2018 11:59 AM|GlobeNewswire|About: PODD 

 COLOGNE, Germany and LITTLETON, Mass., Nov. 06, 2018 (GLOBE NEWSWIRE)  

Aug. 13, 2019 2:31 PM ET | About: Insulet Corporation (PODD) 

 https://seekingalpha.com/article/4285220-insulet-podd-presents-canaccord-genuity-growth-conference-slideshow 

Thu August 15, 2019 4:10 PM|Business Wire|About: RHHBY

– First FDA-approved treatment designed to target both ROS1 and NTRK that also shows response in cancer that has spread to the brain –

– Genentech’s first FDA-approved tumor-agnostic medicine –

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY)

 https://www.gene.com/download/pdf/rozlytrek_prescribing.pdf 

 Medtronic Q2 revenues up 6%; non-GAAP EPS up 14%; raises revenue growth guidance

Nov. 20, 2018 7:10 AM ET|About: Medtronic plc (MDT)|By: Mamta Mayani, SA News Editor  

 AbbVie to Highlight Breadth of Innovative Science and Ongoing Commitment to Blood Cancer Patients with New Data From Studies of Ibrutinib and Venetoclax at 2018 American Society of Hematology Annual Meeting & Exposition

Tue November 20, 2018 8:32 AM|PR Newswire|About: ABBV 

 FDA accepts Allergan's sNDA for AVYCAZ

Nov. 20, 2018 7:54 AM ET|About: Allergan plc (AGN)|By: Mamta Mayani, SA News Editor  

 Mazor Robotics Shareholders Approve Merger Agreement With Medtronic

Mon November 19, 2018 5:30 PM|PR Newswire|About: MDT, MZOR, MZRTF 

 Sandoz and Pear Therapeutics announce launch of reSET® for treatment of patients with Substance Use Disorder

Mon November 19, 2018 6:46 PM|GlobeNewswire|About: NVS 

 Novartis' Entresto beats enalapril in heart failure study

Nov. 12, 2018 7:46 AM ET|About: Novartis AG (NVS)|By: Douglas W. House, SA News Editor  

 FDA Safety Study of Unloading the Left Ventricle for 30 Minutes Prior to Reperfusion in Heart Attack Patients is Safe and Feasible

Abiomed will initiate pivotal randomized controlled trial with FDA

CHICAGO--(BUSINESS WIRE)--Nov. 11, 2018-- Abiomed (NASDAQ: ABMD)

 Singapore National Eye Centre, Singapore Eye Research Institute And Johnson & Johnson Vision Set Sights On Halting Global Myopia Epidemic

Mon November 12, 2018 1:30 AM|PR Newswire|About: JNJ 

 SINGAPORE, Nov. 12, 2018 /PRNewswire/ 

 FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for the Treatment of Patients with Hepatocellular Carcinoma (HCC) Who Have Been Previously Treated with Sorafenib

Fri November 9, 2018 4:21 PM|Business Wire|About: MRK 

 Illumina’s Growth Shows No Signs of Slowing Down

Illumina's recent acquisition of Pacific Biosciences of California strongly strengthens its product offering and ensures growth for years to come

 Maxwell Koobatian 

 November 12, 2018 | About: ILMN +0% PAC 

Thu August 15, 2019 4:01 PM|Business Wire|About: GILD, GLPG

FOSTER CITY, Calif. & MECHELEN, Belgium--(BUSINESS WIRE)-- Gilead Sciences, Inc. (GILD) and Galapagos NV (GLPGF) (Euronext & NASDAQ: GLPG) 

AcelRx announces FDA approval of DSUVIA™ 

 REDWOOD CITY, Calif., Nov. 2, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (AcelRx) (Nasdaq: ACRX),  

  AcelRx Pharmaceuticals... (ACRX) 

 U.S. FDA Approves LORBRENA® (lorlatinib) for Previously-Treated ALK-Positive Metastatic NSCLC

Fri November 2, 2018 4:42 PM|Business Wire|About: PFE 

 Novartis data at ASH and SABCS show strength of pipeline and portfolio in hematology and oncology

Fri November 2, 2018 5:27 PM|PR Newswire|About: NVS 

 EAST HANOVER, N.J., Nov. 2, 2018 /PRNewswire/  

  August 14, 2019 at 7:00 AM EDT Back

TARRYTOWN, N.Y., Aug. 14, 2019 /PRNewswire/ --

Adding evinacumab reduced LDL cholesterol by 49% in patients with homozygous familial hypercholesterolemia, compared to lipid-lowering therapies alone

Evinacumab was generally well-tolerated, and all evinacumab patients completed the six-month treatment period

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN

Tue August 27, 2019 8:30 AM|Business Wire|About: ALXN

 - SOLIRIS® (eculizumab) is the first and only approved medication for NMOSD in Europe -

- 98% of adult anti-aquaporin-4 (AQP4) antibody-positive patients treated with SOLIRIS were relapse free compared to 63% receiving placebo at 48 weeks -

BOSTON--(BUSINESS WIRE)-- Alexion Pharmaceuticals, Inc. (ALXN) 

 BeiGene to Present Clinical Data on PARP Inhibitor Pamiparib at Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology

Mon November 5, 2018 7:00 AM|GlobeNewswire|About: BGNE 

 Amgen Receives CHMP Positive Opinion To Expand Use Of BLINCYTO® (Blinatumomab) In Patients With Minimal Residual Disease-Positive B-Cell Precursor Acute Lymphoblastic Leukemia

Fri November 16, 2018 9:00 AM|PR Newswire|About: AMGN 

 Seattle Genetics Announces FDA Approval of ADCETRIS® (Brentuximab Vedotin) in Combination with Chemotherapy for Adults with Previously Untreated Systemic Anaplastic Large Cell Lymphoma or Other CD30-Expressing Peripheral T-Cell Lymphomas

Fri November 16, 2018 10:52 AM|Business Wire|About: SGEN 

 Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Approval of Opdivo® (nivolumab) Plus Low-Dose Yervoy® (ipilimumab) as First-Line Treatment for Patients with Intermediate- and Poor-Risk Advanced Renal Cell Carcinoma

Thu November 15, 2018 4:30 PM|Business Wire|About: BMY 

 ACUVUE OASYS with Transitions Light Intelligent Technology Named Among TIME's 'Best Inventions of 2018'

Fri November 16, 2018 7:03 AM|PR Newswire|About: JNJ 

 JACKSONVILLE, Fla., Nov. 16, 2018 /PRNewswire/ 

 Agilent Expands Cell Analysis R&D Capabilities in Ireland

Fri November 16, 2018 11:00 AM|Business Wire|About: A 

 BeiGene's pamiparib shows positive action in Phase 1/2 brain cancer study

Nov. 16, 2018 7:56 AM ET|About: BeiGene (BGNE)|By: Douglas W. House, SA News Editor  

 FDA Grants Priority Review to Genentech’s Tecentriq in Combination with Abraxane for the Initial Treatment of People with PD-L1-Positive, Metastatic Triple-Negative Breast Cancer

Tue November 13, 2018 1:06 AM|Business Wire|About: RHHBY 

JPOD   @ Philadelphia officially launched at Pennovation Works
JPOD @ Philadelphia, the first of its kind in the   nation, is a networking hub that includes a secure telecommunications   conferencing system to connect regional innovators to the J&J Innovation   and JLABS network. It's about leveraging the talent-particularly in the health   sciences-that is rampant and unique to Philadelphia, as well as boosting it.
READ MORE › 

 November 13, 2018

 

 Gilead's GS-9674 shows positive action in mid-stage NASH study

Nov. 9, 2018 8:35 AM ET|About: Gilead Sciences, Inc. (GILD)|By: Douglas W. House, SA News Editor  

 Bausch Health Will Expand Contact Lens Manufacturing Facilities In Rochester, NY And Waterford, Ireland

Tue November 13, 2018 7:00 AM|PR Newswire|About: BHC

LAVAL, Quebec, Nov. 13, 2018 /PRNewswire/ -- Bausch Health Companies Inc. (BHC)

 Akcea up 3% on positive AKCEA-APO(a)-Lrx data

Nov. 12, 2018 2:08 PM ET|About: Akcea Therapeutics (AKCA)|By: Douglas W. House, SA News Editor  

 collaboration partner Novartis (NVS)  

 Intuitive Surgical Is Ironman For Doctors

Nov. 12, 2018 9:02 AM ET|8 comments  | About: Intuitive Surgical, Inc. (ISRG) 

 Rob Koyfman 

 Bristol-Myers Squibb and Infinity Pharmaceuticals Announce a New Clinical Collaboration to Evaluate Opdivo (Nivolumab) in Combination with IPI-549 in Urothelial Cancer

Mon November 5, 2018 6:59 AM|Business Wire|About: BMY, INFI 

 Trulicity® (dulaglutide) demonstrates superiority in reduction of cardiovascular events for broad range of people with type 2 diabetes

Mon November 5, 2018 6:45 AM|PR Newswire|About: LLYPR Newswire

INDIANAPOLIS, Nov. 5, 2018 /PRNewswire/ 

 Amgen And Provention Bio Announce Co-Development Collaboration In Celiac Disease

Mon November 5, 2018 9:00 AM|PR Newswire|About: AMGN, PRVB 

 Intercept Announces New OCA Data to be Presented at The Liver Meeting® 2018

Mon November 5, 2018 7:00 AM|GlobeNewswire|About: ICPT 

 Lilly's Jardiance reduced heart failure hospitalization risk in real-world study

Nov. 5, 2018 7:55 AM ET|By: Douglas W. House, SA News Editor  

 Seattle Genetics Submits Supplemental Biologics License Application for ADCETRIS® (Brentuximab Vedotin) in Frontline Treatment of CD30-Expressing Peripheral T-Cell Lymphomas

Mon November 5, 2018 8:00 AM|Business Wire|About: SGEN 

 Abiomed Announces Q2 FY 2019 Record Revenue of $182 Million, up 37% Over Prior Year

Thu November 1, 2018 7:00 AM|GlobeNewswire|About: ABMD

DANVERS, Mass., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Abiomed, Inc. (ABMD) 

 AbbVie Receives European Commission Approval of VENCLYXTO® (venetoclax) Plus Rituximab for the Treatment of Patients with Chronic Lymphocytic Leukemia Who Have Received at Least One Prior Therapy

Thu November 1, 2018 12:02 AM|PR Newswire|About: ABBV 

 Vertex Pharma's Symkevi OK'd in Europe

Nov. 1, 2018 7:05 AM ET|About: Vertex Pharmaceuticals... (VRTX)|By: Douglas W. House, SA News Editor 

 The Landmark DECLARE-TIMI 58 Cardiovascular Outcomes Trial of FARXIGA in Patients with Type 2 Diabetes to Be Featured at AHA 2018

Thu November 1, 2018 7:00 AM|Business Wire|About: AZN 

 WILMINGTON, Del.--(BUSINESS WIRE)-- AstraZeneca 

 Novo Nordisk Q3 revenues up 4%; 

 Nov. 1, 2018 6:24 AM ET|About: Novo Nordisk A/S (NVO)|By: Mamta Mayani, SA News Editor  

 TG Therapeutics up 7% on positive umbralisib + ublituximab data

Nov. 1, 2018 11:04 AM ET|By: Douglas W. House, SA News Editor  

 The overall response rate (ORR) was 89% (n=8/9) in BTK-refractory chronic lymphocytic leukemia (CLL) patients receiving the combination of umbralisib + ublituximab + Merck's (MRK +0.1%) Keytruda (pembrolizumab).